Table 1 Key costs and inputs to the economic model
Parameter | Value |
|---|---|
Hazard ratio: overall survival, BSC vs. ofatumumab | 1.8727 |
Hazard ratio: progression-free survival, BSC vs. ofatumumab | 1.9608 |
Ofatumumab: cost of therapy initiation | £2047 |
Ofatumumab: cost per 100 mg vial | £182 |
Ofatumumab: concomitant medication cost | £104 |
Ofatumumab: cost per chemotherapy administration | £203 |
BSC: cost of therapy initiation | £1470 |
All therapies: cost per month of routine management | £158 |
Utility: progression-free survival | 0.65 |
Utility: post-progression survival | 0.47 |